Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BIO
HOLDBio-Rad Laboratories, Inc. · Healthcare · United States · $8.4B · Avg Vol: $99M/d
COMPANY DESCRIPTION
Bio-Rad Laboratories, Inc. develops, manufactures, and markets a comprehensive range of innovative instruments, reagents, and software for both life science research and clinical diagnostic markets worldwide. The company's competitive moat is established through its diverse portfolio of proprietary technologies, robust R&D pipeline, and a significant installed base of instruments that generate recurring revenue from consumables. Bio-Rad is a global leader in scientific instrumentation, recognized for its broad product catalog and scientific expertise.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.8B | 2.7B | 2.6B | 2.6B | -2.7% | 2.6B | 2.6B | 2.6B | 1.0% |
| EPS | -121.79 | -21.82 | -65.36 | 27.87 | — | 6.00 | 25.29 | 27.31 | -1.0% |
| Shares | 29.6M | 28.5M | 28.0M | 27.0M | -8.8% | 21.7M | — | — | — |
| Debt | 1.4B | 1.4B | 1.4B | 1.4B | -0.0% | 1.4B | — | — | — |
| Equity | 9.6B | 8.7B | 6.6B | 7.5B | -8.1% | — | — | — | — |
| Op CF | 194.4M | 374.9M | 455.2M | 532.2M | 39.9% | 510.4M | — | — | — |
| Inv CF | -1.2B | 20.2M | -160.2M | -189.7M | — | — | — | — | — |
| Fin CF | 973.6M | -425.6M | -218.8M | -283.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BIO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BIO | Bio-Rad Laboratories, Inc.(you) | $8.4B | 63 | HOLD |
| BRKR | Bruker Corporation | $9.2B | 59 | HOLD |
| PEN | Penumbra, Inc. | $12.5B | 53 | HOLD |
| PODD | Insulet Corporation | $11.3B | 47 | HOLD |
| GEHC.MX | GE HealthCare Technologies Inc. | $27.5B | 67 | BUY |
| AXGN | Axogen, Inc. | $2.1B | 63 | HOLD |
| GKOS | Glaukos Corporation | $9.0B | 35 | HOLD |
| ITGR | Integer Holdings Corporation | $3.3B | 73 | BUY |
| GMED | Globus Medical, Inc. | $10.4B | 93 | STRONG BUY |
| STE | STERIS plc | $20.9B | 81 | STRONG BUY |
Peer medians: ROE -25.6% · P/E 27.5x · Gross margin 50.5%